Q32 Bio prices a $200M follow-on offering at $18.25 per share, capturing a 63% premium to the pre-data price
QTTB has more than doubled off its 52-week low of $1.569 on elevated volume (5.1× avg).
Summary
Q32 Bio priced a $200 million follow-on offering at $18.25 per share, a 63% premium to the pre-data price, leveraging positive Phase 2a alopecia data to fund pivotal trials.
Key Events · Financing and Capital Events · QTTB
-
$200M Follow-On Priced at $18.25/Share
The offering consists of 6,027,399 common shares and pre-funded warrants for 4,931,506 shares, priced at $18.25 and $18.2499 respectively, yielding total gross proceeds of $200 million. Underwriters also hold a 30-day option to purchase up to 1,643,835 additional shares.
-
63% Premium to Pre-Data Price
At $18.25, the offering price commands a 63% premium over the $11.21 closing price on July 10, 2026, before the positive Phase 2a bempikibart data emerged, underscoring strong institutional demand.
-
Net Proceeds of ~$187.6 Million
After deducting underwriting discounts of $1.095 per unit and estimated expenses, net proceeds come to approximately $187.6 million, extending the cash runway to support advancement of bempikibart into pivotal trials.
-
Dilution of ~42% on Fully Exercised Basis
If the greenshoe and pre-funded warrants are fully exercised, outstanding shares rise from roughly 23.7 million to about 33.7 million, representing dilution of approximately 42% for existing shareholders.
Analysis · QTTB · Life Sciences
Capitalizing on robust institutional demand after positive Phase 2a alopecia data, Q32 Bio priced a $200 million public offering at $18.25 per share — a 63% premium to the $11.21 close just before the readout. The deal comprises 6.0 million common shares and pre-funded warrants covering 4.9 million more, with a 30-day greenshoe for an additional 1.6 million shares. Net proceeds of roughly $187.6 million extend the cash runway well into the pivotal trial phase for bempikibart. While the premium pricing reflects enthusiasm following the 35.3% mean SALT reduction, the offering still dilutes existing shareholders by about 42% on a fully exercised basis. This marks the third capital raise in three months, following a $55 million private placement in May and ATM sales, bringing total recent financing to over $250 million.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QTTB was trading at $16.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $371.8M. The 52-week trading range was $1.57 to $23.57. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.